drugset / Trial / NCT01696877
A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer
Phase 1/2
Completed
29 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
BioSante Pharmaceuticals · collabDavid H. Koch Charitable Foundation · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This research is being done to see if an investigational prostate cancer vaccine, called GVAX, can safely be given together with a single intravenous injection of a drug called cyclophosphamide to men that will undergo surgery to remove their cancerous prostate glands who have also received standard hormonal therapy.
Timeline
- Start
- 2013-01-18
- Primary completion
- 2017-08
- Completion
- 2018-12-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 200 mg/m2 | Intravenous |
| Subject | Degarelix | Other / unclassified | 240 mg | Subcutaneous |
| Subject | GVAX | Vaccine | 5e+08 cells | Other |